Press Release - A drug currently approved for smallpox in the U.S. will undergo clinical trials to treat patients infected by the Mpox viruswho are at risk of severe complications in the Democratic ...

Detailed price information for Emergent Biosolutions (EBS-N) from The Globe and Mail including charting and trades.

The trial will be conducted in the Democratic Republic of the Congo in partnership with Emergent BioSolutions.

Meanwhile, COVID activity remained low amid a shift in variant proportions and RSV levels rose in 3 US regions.

Emergent BioSolutions' Q3 earnings report drives 20% surge in share price, reflecting market optimism. See why award a ...

Emergent Biosolutions ( (EBS) ) has released its Q3 earnings. Here is a breakdown of the information Emergent Biosolutions presented to its ...

Emergent BioSolutions (EBS) is up 23.7%, or $2.18 to $11.38. Published first on TheFly – the ultimate source for real-time, ...

Thursday after the company reported strong third-quarter results, lifting retail sentiment. Earnings per share for Q3 came in ...

Concurrently, Emergent BioSolutions announced that brincidofovir (brand name Tembexa for smallpox treatment) will be included ...

Shares of Emergent Biosolutions climbed after the company reported an increase in revenue and swung to a profit in the third quarter. The stock was up 28% to $11.81 in Thursday afternoon trading.

Emergent BioSolutions raised its revenue guidance and dropped a going concern warning. Its CEO is billing this next chapter ...

European shares closed mostly higher today. The eurozone's STOXX 600 gained 0.62%, Germany's DAX gained 1.70% and France's ...